GSK’s (GSK) “Buy” Rating Reaffirmed at Jefferies Financial Group

GSK (LON:GSK)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Financial Group in a research report issued to clients and investors on Tuesday, Digital Look reports. They currently have a GBX 2,500 target price on the stock. Jefferies Financial Group’s target price indicates a potential upside of 34.16% from the stock’s previous close.

Several other brokerages have also issued reports on GSK. Berenberg Bank increased their price target on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a report on Tuesday, September 15th. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 1,975 price objective on shares of GSK in a report on Tuesday, September 8th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a report on Tuesday, September 29th. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of GBX 2,064.38.

GSK Price Performance

Shares of LON GSK opened at GBX 1,863.50 on Tuesday. The firm has a market capitalization of £74.67 billion, a P/E ratio of 15.82, a P/E/G ratio of 1.24 and a beta of 0.29. The firm’s 50-day moving average price is GBX 1,845.67 and its 200-day moving average price is GBX 1,924.07. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. GSK has a 1-year low of GBX 1,592 and a 1-year high of GBX 2,282.

GSK (LON:GSK) last issued its earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. Equities research analysts anticipate that GSK will post 175.98 earnings per share for the current fiscal year.

Insider Transactions at GSK

In other GSK news, insider Jonathan Symonds bought 1,500 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were bought at an average price of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal purchased 637 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The stock was acquired at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. Insiders purchased a total of 2,151 shares of company stock worth $6,021,921 in the last 90 days. 0.20% of the stock is currently owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.